NCT06168188View on ClinicalTrials.gov

The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic Neuropathy

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 24, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Traumatic Optic Neuropathy
Interventions
DRUG

Neulasta® (pegfilgrastim)

Intravitreal injection of Neulasta® (pegfilgrastim) after TON

Trial Locations (1)

970

RECRUITING

Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taipei

All Listed Sponsors
lead

Buddhist Tzu Chi General Hospital

OTHER

NCT06168188 - The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic Neuropathy | Biotech Hunter | Biotech Hunter